Previous 10 | Next 10 |
Incyte (INCY -2.2%) has extended its post-market losses on Wednesday despite recording better than expected revenue for Q4 2021. Its blockbuster JAK inhibitor, JAKAFI/JAKAVI (ruxolitinib), brought $592M in net product revenue during the quarter with ~15% YoY growth expanding the yearly net pr...
Investing in the biotech industry is an art, not a science. While the potential for gains from groundbreaking therapies exists, the majority fail. By utilizing statistics, careful selection, and net present value calculations, it is quite easy to find a basket that fulfills your p...
Incyte Corporation (INCY) Q4 2021 Earnings Conference Call February 8, 2022 8:00 AM ET Company Participants Christine Chiou – Head-Investor Relations Hervé Hoppenot – Chairman, President and Chief Executive Officer Barry Flannelly – Executive Vice President and Gener...
Incyte's (NASDAQ:INCY) Q4 2021 revenue beat was helped in large part by a 15% year-over-year increase in sales of JAK inhibitor Jakafi (ruxolitinib). Shares are down 1.7% pre-market. Overall, reevenue rose ~9% YoY to $862.5M. Jakafi sales rose to $592M. Incyte also launched Opz...
Incyte press release (NASDAQ:INCY): Q4 EPS of $0.10 may not be comparable to consensus of $0.86. Revenue of $862.5M (+9.2% Y/Y) beats by $49.12M. Total product and royalty revenues of $813 million (+20%) in Q4’21 Jakafi® (ruxolitinib) net product revenues of $592 million (+15...
Total product and royalty revenues of $813 million (+20%) in Q4’21 and $2.891 billion (+17%) in FY’21 Jakafi ® (ruxolitinib) net product revenues of $592 million (+15%) in Q4’21 and $2.135 billion (+10%) in FY’21; Jakafi guidance range of $2.3 ...
Incyte (NASDAQ:INCY) is scheduled to announce Q4 earnings results on Tuesday, February 8th, before market open. The consensus EPS Estimate is $0.86 (-7.5% Y/Y) and the consensus Revenue Estimate is $813.38M (+3.0% Y/Y). Over the last 2 years, INCY has beaten EPS estimates 75% of the time and ...
Updates on OLUMIANT® (baricitinib) Phase 3 lupus program and FDA review for atopic dermatitis PR Newswire INDIANAPOLIS , Jan. 28, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) today announced updates on the Phase 3 deve...
Incyte (Nasdaq:INCY) today announced updates regarding the clinical development of parsaclisib, the Company’s next-generation oral inhibitor of phosphatidylinositol 3-kinase delta (PI3Kδ), and MCLA-145, its CD137/PD-L1 bispecific antibody co-developed under a global collab...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 25, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific...
News, Short Squeeze, Breakout and More Instantly...
2024-07-12 10:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-02 11:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-02 06:15:05 ET BMO Capital analyst issues UNDERPERFORM recommendation for INCY on July 2, 2024 04:26AM ET. The previous analyst recommendation was Market Perform. INCY was trading at $60.87 at issue of the analyst recommendation. The overall analyst consensus : B...